Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study

Yeh Chen Lee [ID] ,[1,2,3] Madeleine T King,[4] Rachel L O'Connell,[2] Anne Lanceley,[5] Florence Joly,[6,7] Felix Hilpert,[8,9] Alison Davis,[1,10] Felicia T Roncolato,[1,2] Aikou Okamoto,[11,12] Jane Bryce,[13,14,15] Paul Donnellan,[16] Amit M Oza,[17,18] Elisabeth Avall-Lundqvist,[19,20,21] Jonathan S Berek,[22,23] Jonathan A Ledermann [ID] ,[24] Dominique Berton,[6,25] Jalid Sehouli,[26,27] Amanda Feeney,[24] Marie-Christine Kaminsky,[6,28] Katrina Diamante,[2] Martin R Stockler,[2] Michael L Friedlander [ID] ,[1,3] for the GCIG Symptom Benefit Group

HIGHLIGHTS

- Most participants reported symptoms related to recurrent ovarian cancer
- 40% of patients symptomatic at baseline reported an improvement in symptoms within 2 months of starting chemotherapy
- Improvements in quality of life were reported by approximately one in six participants on chemotherapy

ABSTRACT

Objective The Gynecologic Cancer InterGroup (GCIG)-Symptom Benefit Study was designed to evaluate the effects of chemotherapy on symptoms and health-related quality of life (HRQL) in women having chemotherapy for platinum resistant/refractory recurrent ovarian cancer (PRR-ROC) and potentially platinum sensitive with ≥3 lines of chemotherapy (PPS-ROC ≥3).

Methods Participants completed the Measure of Ovarian Cancer Symptoms and Treatment (MOST) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30 questionnaires at baseline and every 3–4 weeks until progression. Participants were classified symptomatic if they rated ≥4 of 10 in at least one-third of symptoms in the MOST index. Improvement in MOST was defined as two consecutive scores of ≤3 in at least half of the symptomatic items at baseline. Improvement in HRQL was defined as two consecutive scores ≥10 points above baseline in the QLQ-C30 summary score scale (range 0–100).

Results Of 948 participants enrolled, 910 (96%) completed baseline questionnaires: 546 with PRR-ROC and 364 with PPS-ROC ≥3. The proportions of participants symptomatic at baseline as per MOST indexes were: abdominal 54%, psychological 53%, and disease- or treatment-related 35%. Improvement was reported in MOST indexes: abdominal 40%, psychological 35%, and disease- or treatment-related 38%. Median time to improvement in abdominal symptoms occurred earlier for PRR-ROC than for PPS-ROC ≥3 (4 vs 6 weeks, p=0.044); median duration of improvement was also similar (9.0 vs 11.7 weeks, p=0.65). Progression-free survival was longer among those with improvement in abdominal symptoms than in those without (median 7.2 vs 2.5 months, p<0.0001). Improvements in HRQL were reported by 77/448 (17%) with PRR-ROC and 61/301 (20%) with PPS-ROC ≥3 (p=0.29), and 102/481 (21%) of those with abdominal symptoms at baseline.

Conclusion Over 50% of participants reported abdominal and psychological symptoms at baseline. Of those, 40% reported an improvement within 2 months of starting chemotherapy. Approximately one in six participants reported an improvement in HRQL. Symptom monitoring and supportive care is important as chemotherapy palliated less than half of symptomatic participants.

BACKGROUND

Patients with platinum resistant/refractory recurrent ovarian cancer (PRR-ROC) and potentially platinum sensitive recurrent ovarian cancer following ≥3 lines of prior chemotherapy (PPS-ROC ≥3) often experience a multitude of symptoms related to disease progression and cumulative toxicities from prior chemotherapy.[1] It can be difficult to distinguish between disease- and chemotherapy-related symptoms such as fatigue, nausea and constipation, among others. Many patients also experience anxiety and depression.[2] The goals of chemotherapy in this setting include palliating symptoms, improving health-related quality of life (HRQL), and delaying disease progression. Despite decades of chemotherapy trials in recurrent ovarian cancer, there is uncertainty about how well 'palliative' chemotherapy improves symptoms as this is not usually assessed or reported in clinical trials.[3]

Few trials in recurrent ovarian cancer have reported the effects of chemotherapy either on symptoms or on improvements in HRQL.[4–7] Trials of chemotherapy in PRR-ROC have reported median progression-free

survival of 3–4 months and objective tumor response rates of 4–20%.[8] Although objective tumor response rates are higher in PPS-ROC ≥3, the likelihood of response and the duration of response decrease with each subsequent line of chemotherapy and are similar to those reported in PRR-ROC.[9][10] Given that chemotherapy is meant to palliate symptoms, it is important to document the nature and burden of symptoms at baseline, and to evaluate the impact of chemotherapy on symptoms and HRQL.[4][7]

Based on data from the Gynecologic Cancer InterGroup (GCIG)-Symptom Benefit Study, we have previously reported the predictors of stopping chemotherapy early and survival outcome in patients with PRR-ROC and PPS-ROC≥3.[11][12] We report here on their symptom burden at baseline, rates of improvement in symptoms with chemotherapy, time to improvement of symptoms, and duration of improvement. We also report the overall HRQL at baseline, rates of improvement with chemotherapy, and the correlation with the reported improvement in symptoms. The rationale for the study was to inform discussions with patients and their families about the possible benefits and harms of palliative chemotherapy in recurrent ovarian cancer, and to enable the inclusion of symptom benefit as an endpoint in future clinical trials.

METHODS

GCIG-Symptom Benefit Study
The GCIG-Symptom Benefit Study (clinical trial registration number ACTRN12607000603415, Online supplemental file 1) was a prospective observational cohort study. Stage 1 has been reported.[1] Stage 2 aimed to determine the proportion of women benefiting from palliative chemotherapy as defined by a clinically significant improvement in HRQL scores and improvement of symptoms. Participants had either PRR-ROC or PPS-ROC ≥3 and had been recommended palliative chemotherapy by their treating clinician.[13] The study was in accordance with the NHMRC Statement on Ethical Conduct in Research Involving Humans and the Declaration of Helsinki, with ethics approval at all participating sites and signed written informed consent was obtained from all participants.

Symptoms and aspects of HRQL were assessed with the Measure of Ovarian cancer Symptoms and Treatment (MOST-T35),[13][14] European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30,[15][16] QLQ-OV28,[17] Functional Assessment of Cancer Therapy-Ovarian (FACT-O),[18] and Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI).[19] Participants completed these questionnaires without assistance on paper while waiting to see their physicians at baseline and before each cycle of chemotherapy until disease progression. Participants were included in the analysis if they completed a questionnaire at baseline and at least one subsequent time point.

Symptom Assessment with MOST-T35
Symptoms and well-being were assessed with MOST-T35,[14] which includes 35 items. Three items assess well-being (physical, emotional, overall) on a numeric rating scale from 0 (worst possible) to 10 (best possible). The remainder assess symptoms and treatment-related difficulties on a rating scale from 0 (none at all) to 10 (worst I can imagine), with additional verbal anchors for mild (1–3), moderate (4–6), and severe (7–9). Twenty-four of these items were grouped into five indexes: abdominal (MOST-Abdo,

2 symptoms), disease- or treatment-related (MOST-DorT, 11 symptoms), chemotherapy-related (MOST-Chemo, 6 symptoms), psychological (MOST-Psych, 2 symptoms), and well-being (MOST-Well-being, 3 items).[13] Index scores were calculated as the average of the component items, linearly transformed to give a score from 0 (none at all) to 100 (most severe) for the four symptom indexes and 0 (worst possible) to 100 (best possible) for the well-being index.[13]

Patients were categorized as symptomatic at baseline if they scored ≥4 out of 10 (verbal anchors of moderate, severe, and worst I can imagine) for at least one-third of the items in a MOST symptom index: 1 of 2 items for MOST-Abdo and MOST-Psych, 4 of 11 items for MOST-DorT, and 2 of 6 items for MOST-Chemo. Symptom improvement was defined as ≥2 consecutive scores of ≤3 in items that were symptomatic at baseline and required at least two symptoms for MOST-Chemo and MOST-DorT and at least one symptom for MOST-Abdo and MOST-Psych to improve. For the MOST-Well-being index, a score of ≤6 in at least one well-being item at baseline was considered to represent impaired well-being, and improvement was defined as a score of ≥7 in at least one of the items that scored ≤6 at baseline.

HRQL Assessment with EORTC QLQ-C30 and QLU-C10D
Aspects of HRQL were measured with the EORTC QLQ-C30 which includes 30 items that collectively assess five aspects of functioning (physical, role, cognitive, emotional, and social functioning), eight symptoms commonly experienced by cancer patients, financial difficulties, and a global rating of health and quality of life.[15][16]

In this analysis we took two approaches to scoring data from the QLQ-C30 to provide a comprehensive measure of aspects of HRQL. The first was to use the QLQ-C30 summary score, which incorporates 27 items (excluding three items: financial difficulties, global quality of life, and health).[20][21] A higher score of QLQ-C30 summary score indicates a better HRQL. An improvement in overall HRQL was defined as two or more consecutive summary scores that were ≥10 points higher than the summary score at baseline.

The second approach was to use the EORTC QLU-C10D utility score which incorporates 13 items from the QLQ-C30 covering physical, emotional, role, and social functioning, plus symptoms often experienced by patients with ovarian cancer (fatigue, pain, nausea, sleep problems, bowel problems, and appetite loss).[22] Validated Australian utility weights were used, resulting in a score from −0.095 (worst) to 1 (best).[23] An improvement in the QLU-C10D utility score was defined as ≥2 consecutive scores that were ≥0.10 higher than the score at baseline.

Statistical Analysis
Continuous variables are reported as mean or median (IQR). Counts with percentages are reported for categorical variables. The χ^2 test was used to compare proportions and the Wilcoxon rank-sum test was used for comparisons of non-normally distributed continuous variables. We used the Kaplan–Meier method and log rank test to analyze progression-free survival. Statistical inferences were based on a two-sided significance level of 0.05 without correction for multiplicity. Analyses were performed with SAS version 9.4 and R version 3.6.3.

Table 1 Numbers of participants completing patient-reported outcome measures (PROMs) at each time point

Time point	Baseline	Pre-C2	Pre-C3	Pre-C4	Pre-C5	Pre-C6	Pre-C7
PROM completed/ number proceeding with chemotherapy* (%)	910/933 (98%)	765/838 (91%)	611/673 (91%)	452/499 (91%)	361/406 (89%)	250/286 (87%)	126/150 (84%)
PROM completed but chemotherapy discontinued	0	29	75	101	65	113	159
PROM completed according to treatment group							
PRR-ROC, n_1	546	461	390	293	222	189	136
PPS-ROC ≥3, n_2	364	333	296	260	204	174	149

*Number of participants who completed PROM questionnaires divided by number of participants proceeding with chemotherapy.
C, chemotherapy cycle; PPS-ROC ≥3, potentially platinum sensitive recurrent ovarian cancer after ≥3 lines of chemotherapy; PROM, patient reported outcome measure; PRR-ROC, platinum resistant/refractory recurrent ovarian cancer.

RESULTS

We recruited 948 participants to GCIG-Symptom Benefit Study stage 2, of whom 933 (98%) received at least one cycle of chemotherapy. This study was an expansion of stage 1, which reported a high symptom burden in 126 participants with PRR-ROC at baseline, of which almost 50% of symptomatic participants reported symptom improvement.[1] Baseline questionnaires were completed by 910 of 933 (98%) patients: 546 (60%) with PRR-ROC and 364 (40%) with PPS-ROC ≥3. Questionnaire completion rates (number who completed questionnaires divided by number continuing chemotherapy) were 84% or higher at all time points (Table 1). Patients who ended the chemotherapy cycle but continued to complete questionnaires are also shown in Table 1. Six or more cycles of chemotherapy were administered in 28% (162/570) of those with PRR-ROC and 33% (124/379) of those with PPS-ROC ≥3.

Baseline Symptom Burden and Symptom Improvement on Chemotherapy According to MOST Indexes

The numbers and proportions of women classified as symptomatic at baseline according to the five MOST indexes, the number showing an improvement in symptoms and well-being, and the time to improvement in symptoms are shown in Table 2 for all participants and for the sub-groups with PRR-ROC and PPS-ROC ≥3.

At baseline, before starting chemotherapy, approximately half the participants were classified as symptomatic according to the MOST-Abdo index (481/893, 54%) or MOST-Psych index (472/896, 53%), one-third according to the MOST-DorT index (314/903, 35%), and one-quarter according to the MOST-Chemo index (244/898, 27%). Approximately three-quarters of all participants were classified as having impaired well-being at baseline (633/883, 72%). These proportions were similar among those with PRR-ROC and those with PPS-ROC ≥3 (all p>0.16).

Among participants classified as symptomatic at baseline, improvements during chemotherapy were observed in approximately 40% according to MOST-Abdo (190/481, 40%) and MOST-DorT (118/314, 38%), one-third according to MOST-Psych (165/472, 35%), and one-quarter according to MOST-Chemo (68/244, 28%) and MOST-Well-being (156/633, 25%). Improvements occurred with similar frequencies among those with PRR-ROC and PPS-ROC ≥3.

The median time to improvement in symptoms ranged from 4 to 7 weeks. Improvements in MOST-Abdo occurred earlier for those with PRR-ROC than PPS-ROC ≥3 (median 4 vs 6 weeks, p=0.044). The median time to improvement in MOST-Well-being was 5–6 weeks. The median duration of improvement in MOST-Abdo symptoms among all participants was 10 weeks (IQR 4–20) and was similar among those with PRR-ROC and those with PPS-ROC ≥3 (9.0 vs 11.7 weeks, p=0.65).

Progression-free survival was longer among participants with abdominal symptoms at baseline that improved than in those with abdominal symptoms that did not improve (median 7.2 vs 2.5 months, p<0.0001; Figure 1). Participants without abdominal symptoms at baseline had a median progression-free survival of 5.3 months.

HRQL Improvement According to the EORTC QLQ-C30 Summary Score and QLU-C10D Utility Score

At baseline, before starting chemotherapy, the proportion of participants who reported reduced HRQL (EORTC QLQ-C30 summary score ≤90 points on a range from 0 to 100) was similar for PRR-ROC (448/516, 87%) and PPS-ROC ≥3 (301/349, 86%). Improvements in HRQL were recorded with similar frequency among those with PRR-ROC and those with PPS-ROC ≥3 (77/448 (17%) vs 61/301 (20%), p=0.29). The median time to improvement in summary score for HRQL was 5 weeks and 9 weeks, respectively (p=0.06).

In general, QLQ-C30 summary scores were higher among participants who completed a larger number of assessments, and summary scores declined as participants approached their last assessments (Figure 2). At baseline, a QLU-C10D score ≤0.9 (on a scale from −0.095 to 1.0) was reported by the same proportions of participants with PRR-ROC (469/509, 92%) and PPS-ROC ≥3 (313/342, 92%). An improvement in HRQL according to the QLU-C10D was reported by fewer participants with PRR-ROC than PPS-ROC ≥3 (90/469 (19%) vs 82/313 (26%), p=0.02). Time to improvement in the QLU-C10D score was somewhat shorter among

Table 2 Burden at baseline and subsequent improvements in symptoms and well-being assessed with MOST index scores

MOST indexes	All participants		PRR-ROC		PPS-ROC ≥3		P value* n_1 vs n_2
	N_0	Symptomatic at baseline, n_0 (%)	N_1	Symptomatic at baseline, n_1 (%)	N_2	Symptomatic at baseline, n_2 (%)	
MOST-Abdo†	893	481 (54)	535	296 (55)	358	185 (52)	0.28
MOST-Psych‡	896	472 (53)	534	278 (52)	362	194 (54)	0.65
MOST-DorT§	903	314 (35)	540	192 (36)	363	122 (34)	0.55
MOST-Chemo¶	898	244 (27)	537	155 (29)	361	89 (25)	0.16
MOST-Well-being**	883	633 (72)	527	377 (72)	356	256 (72)	0.90
	N_0	Symptom improvement, n_0 (%)	N_1	Symptom improvement, n_1 (%)	N_2	Symptom improvement, n_2 (%)	P value* n_1 vs n_2
MOST-Abdo	481	190 (40)	296	107 (36)	185	83 (45)	0.06
MOST-Psych	472	165 (35)	278	93 (33)	194	72 (37)	0.41
MOST-DorT	314	118 (38)	192	66 (34)	122	52 (43)	0.14
MOST-Chemo	244	68 (28)	155	50 (32)	89	18 (20)	0.04
MOST-Well-being	633	156 (25)	377	85 (23)	256	71 (28)	0.14
	N_0	Time to improvement, median (IQR) weeks	N_1	Time to improvement, median (IQR) weeks	N_2	Time to improvement, median (IQR) weeks	P value††
MOST-Abdo	190	5 (4–9)	107	4 (4–9)	83	6 (4–12)	0.04
MOST-Psych	165	4 (4–8)	93	4 (4–6)	72	5 (4–14)	0.26
MOST-DorT	118	5 (4–9)	66	5 (4–8)	52	5 (4–10)	0.57
MOST-Chemo	68	5 (4–13)	50	5 (4–13)	18	7 (4–13)	0.54
MOST-Well-being	156	6 (4–12)	85	5 (4–11)	71	6 (4–16)	0.15

*χ^2 test.
†MOST-Abdo, 2 symptoms: abdominal pain, discomfort and/or cramps; abdominal swelling, bloating and/or fullness.
‡MOST-Psych, 2 symptoms: anxiety (feeling worried); depression (feeling sad).
§MOST-DorT, 11 symptoms: fatigue (tiredness); trouble eating; indigestion; nausea; vomiting; diarrhea; constipation; shortness of breath; difficulty swallowing; trouble sleeping; bladder problems.
¶MOST-Chemo, 6 symptoms: altered sense of taste; sore mouth or throat; hair loss; skin rash; numbness or pins and needles; sore hands and feet.
**MOST-Well-being, 3 items: physical well-being, emotional well-being, overall well-being.
††Wilcoxon rank-sum test.
IQR, interquartile range; MOST, Measure of Ovarian Cancer Symptoms and Treatment; n, number; N, denominator; PPS-ROC ≥3, potentially platinum sensitive recurrent ovarian cancer after ≥3 lines of chemotherapy; PRR-ROC, platinum resistant/refractory recurrent ovarian cancer.

those with PRR-ROC than in those with PPS-ROC ≥3 (median 4 vs 7 weeks, p=0.02).

Improvements in Abdominal Symptoms and HRQL

The frequencies of abdominal symptoms, improvements in abdominal symptoms, and improvements in HRQL are shown as an alluvial plot in Figure 3. Approximately half the participants were classified as having abdominal symptoms at baseline according to MOST-Abdo (481/893, 54%). Of those 481 participants, 190 (40%) had an improvement in abdominal symptoms and 102 (21%) had an improvement in HRQL according to the EORTC-QLQ C30 summary score. Among 291 participants with abdominal symptoms at baseline that did not improve, an improvement in HRQL was observed in 21 (7%) participants. An improvement in HRQL was observed in 33 of 412 (8%) participants without abdominal symptoms.

DISCUSSION

Summary of Main Results

Our findings confirmed that patients with PRR-ROC and PPS-ROC ≥3 had a high burden of symptoms related to their disease and chemotherapy. Symptom burden at baseline was high and similar among those with PRR-ROC and PPS-ROC ≥3, with over 50% reporting moderate to severe abdominal symptoms (MOST-Abdo) and psychological symptoms (MOST-Psych). Of those symptomatic at baseline, less than 40% reported an improvement in symptoms with chemotherapy. Overall, approximately 15% of participants reported an improvement in aspects of HRQL with chemotherapy. These findings are sobering and demonstrate that only a relatively small proportion of patients overall experience improvement in their symptoms and quality of life as a result of palliative chemotherapy.

Figure 1 Progression-free survival for sub-groups with symptoms at baseline that improved, symptoms at baseline that did not improve, and no symptoms at baseline.

Results in the Context of Published Literature

Our findings underscore the importance of assessing symptoms at baseline and during chemotherapy. Similar to PRR-ROC, participants with PPS-ROC ≥3 were found to have a high symptom burden at baseline and marginally higher numerical improvement in symptoms with chemotherapy. Importantly, relative to patients with one or two lines of treatment, our findings showed that the benefit of chemotherapy was low in those who had ≥3 lines of chemotherapy despite being considered to be potentially platinum sensitive, which is in keeping with the clinical observation in routine practice as well as a study reported by Hanker et al.[10] Our findings also highlight the need to temper patient expectations about the likelihood that symptoms and quality of life will improve with chemotherapy.

The goals of treatment in PRR-ROC and PPS-ROC ≥3 include palliation of symptoms and delaying cancer progression; our results indicate the limited capacity for chemotherapy to achieve



Figure 2 European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30 summary scores for overall quality of life by the number of assessment time points at which questionnaires were completed.

*NA for QoL Improvement means the patient scored >90 at baseline

Figure 3 Improvements in abdominal symptoms and overall health-related quality of life (European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30 summary score) according to treatment group and the presence of abdominal symptoms at baseline.

these goals and therefore the importance of supportive care to manage symptoms. We recommend a more comprehensive holistic approach to management and supportive care, including early and routine integration of palliative care, psycho-oncology, and allied health services to address physical, psychological, social, and existential concerns. Moreover, patients' preferences should be included in the treatment decision-making process.[24] Greater attention is also warranted to address side effects of chemotherapy.[25 26]

Improvements in symptoms and/or HRQL were generally evident within 4–6 weeks (2–3 cycles of chemotherapy). Those with abdominal symptoms at baseline that improved during chemotherapy had a median duration of symptom improvement of 10 weeks and median progression-free survival was 7 months, which is likely a reflection of chemotherapy effect. For the 25% of participants who reported an improvement in MOST-Well-being, the median time to improvement was 6 weeks. Translating these findings into clinical practice, improvements in symptoms and/or HRQL are likely to be observed within 2 months of starting chemotherapy. Persistence of symptoms after 2 months of chemotherapy for PRR-ROC and PPS-ROC ≥3 should trigger reassessment of disease status and careful consideration of whether to continue chemotherapy, increase palliative care involvement, and discuss advanced care planning.

Many patients will persevere through disease-related symptoms and treatment-related side effects in the hope of a tumor response or delayed progression and longer survival. In reality, response rates reported for single agent chemotherapy in PRR-ROC range from 4% to 15% and the impact on overall survival is unclear.[8] This study showed that regular assessment of symptoms with MOST could help reveal trends in symptoms and well-being that could complement tumor markers and imaging as indicators of treatment benefit. In addition, using MOST would provide a patient-rated measure of chemotherapy toxicities to counter the well-documented under-reporting of toxicities inherent in clinicians' assessments.[1 27 28]

Strengths and Weaknesses of Study

This study describes the impact of palliative chemotherapy on symptoms and HRQL in a large international real-world patient sample using a dataset of patient-rated outcome measures with excellent (≥84%) completion rates. Our study demonstrates the importance of regular assessment of symptoms during chemotherapy and underscores the critical importance of supportive care and symptom management beyond the administration of chemotherapy alone. One limitation of our study was that our patient-reported outcome data were collected for research and not relayed to the treating clinicians in real time.

Implications for Practice and Future Research

Future research should involve systematic collection of patient-reported outcome measures and real-time reporting to their clinicians, as this can improve patient–clinician communication, responsiveness of clinicians to patients' individual care needs, and patients' understanding and awareness of symptoms.[29 30] A systematic review of 22 randomized trials found that proactive use of patient-reported outcome measures in clinical care can be beneficial, particularly when the results were provided to treating clinicians in real time,[29 31 32] but these are not beneficial in all contexts. One of the most influential trials reported improvements in HRQL and overall survival using self-ratings of 12 symptoms commonly experienced during chemotherapy,[31 33] including nine of the symptoms assessed by MOST. Timely and tailored symptom management of patients receiving chemotherapy for ovarian cancer could improve patients' tolerance of chemotherapy.

MOST is an instrument tailored to symptoms and concerns pertinent to ovarian cancer and its treatment. Accordingly, we propose MOST as a suitable candidate for integration into the care of women having treatment for recurrent ovarian cancer, with results reviewed by clinicians in real time. This could improve patients' understanding and encourage them to report key symptoms that occur between clinic visits. Future research in this area is needed,

and in line with a position statement by the GCIG-Symptom Benefit Committee urging the incorporation of patient-centered benefits as end points for trials in ovarian cancer.[34]

CONCLUSION

Improvement in symptoms was seen in approximately 40% of those with moderate or severe symptoms at baseline, with a median time to improvement of <2 months. However, many participants did not experience a meaningful improvement in symptoms during chemotherapy. Our findings indicate the need to reassess disease status and decide whether to continue treatment, particularly if symptoms persist beyond 2 months on chemotherapy. In addition, there is a role for using patient-reported outcome measures routinely in clinic to assess symptom benefit during chemotherapy for recurrent ovarian cancer, and the importance of supportive care in this setting.

Author affiliations
[1]Australia New Zealand Gynaecological Oncology Group (ANZGOG), Camperdown, New South Wales, Australia
[2]University of Sydney, NHMRC Clinical Trials Centre, Camperdown, New South Wales, Australia
[3]Prince of Wales Clinical School, Faculty of Medicine and Health, University of New South Wales, Randwick, New South Wales, Australia
[4]University of Sydney, Quality of Life Office of Psycho-Oncology Research Group (PoCoG), Camperdown, New South Wales, Australia
[5]UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK
[6]GINECO-Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Paris, France
[7]Oncology, Ctr Francois Baclesse, Caen, France
[8]Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe (AGO) und North-Eastern German Society of Gynecologcial Oncology (NOGGO), Kiel, Germany
[9]Onkologisches Therapiezentrum, Krankenhaus Jerusalem, Hamburg, Germany
[10]Medical Oncology, Canberra Hospital, Canberra, Australian Capital Territory, Australia
[11]Japanese Gynecologic Oncology Group (JGOG), Tokyo, Japan
[12]Department of Obstetrics and Gynecology, Jikei University School of Medicine, Minato-ku, Japan
[13]Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy
[14]Ascension St John Clinical Research Institute, Tulsa, Oklahoma, USA
[15]MITO Multicentre Italian Trials in Ovarian and gynecologic cancer, Italy
[16]Cancer Trials Ireland, Galway University Hospital, Galway, Ireland
[17]Princess Margaret Consortium (PMHC), Toronto, Ontario, Canada
[18]Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada
[19]Nordic Society of Gynaecological Oncology (NSGO), Copenhagen, Denmark
[20]Department of Oncology and Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden
[21]Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
[22]Cooperative Gynecologic Oncology Investigators (COGI), Stanford, California, USA
[23]Stanford Women's Cancer Centre, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA
[24]The Cancer Research UK and UCL Cancer Trials Centre, NCRI UK, London, UK
[25]Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Saint Herblain, France
[26]Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe (AGO) und North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin, Germany
[27]Department of Gynecology and Oncological Surgery, Charité Universitätsmedizin Berlin, Berlin, Germany
[28]Institut de Cancérologie de Lorraine, Vandoeuvre Les Nancy, France

Twitter Yeh Chen Lee @YChenLee

Original research

ORCID iDs

Yeh Chen Lee http://orcid.org/0000-0003-2009-8263
Jonathan A Ledermann http://orcid.org/0000-0003-3799-3539
Michael L Friedlander http://orcid.org/0000-0003-3090-795X

REFERENCES

1 Friedlander ML, Stockler M, O'Connell R, *et al*. Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the Gynecologic Cancer Intergroup Symptom Benefit Study. *Int J Gynecol Cancer* 2014;24:857–64.

2 Hwang K-H, Cho O-H, Yoo Y-S. Symptom clusters of ovarian cancer patients undergoing chemotherapy, and their emotional status and quality of life. *Eur J Oncol Nurs* 2016;21:215–22.

3 Friedlander M, Mercieca-Bebber RL, King MT. Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned. *Ann Oncol* 2016;27 Suppl 1:i66–71.

4 Wilson MK, Friedlander ML, Joly F, *et al*. A systematic review of health-related quality of life reporting in ovarian cancer phase III clinical trials: room to improve. *Oncologist* 2018;23:203–13.

5 Joly F, Hilpert F, Okamoto A, *et al*. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer. *Eur J Cancer* 2017;78:133–8.

6 Stockler MR, Hilpert F, Friedlander M, *et al*. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. *J Clin Oncol* 2014;32:1309–16.

7 Lindemann K, Gibbs E, Åvall-Lundqvist E, *et al*. Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). *Br J Cancer* 2017;116:455–63.

8 Pujade-Lauraine E, Banerjee S, Pignata S. Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives. *J Clin Oncol* 2019;37:2437–48.

9 Matulonis UA. Management of newly diagnosed or recurrent ovarian cancer. *Clin Adv Hematol Oncol* 2018;16:426–37.

10 Hanker LC, Loibl S, Burchardi N, *et al*. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. *Ann Oncol* 2012;23:2605–12.

11 Roncolato FT, Joly F, O'Connell R, *et al*. Reducing uncertainty: predictors of stopping chemotherapy early and shortened survival time in platinum resistant/refractory ovarian cancer-the GCIG Symptom Benefit Study. *Oncologist* 2017;22:1117–24.

12 Roncolato FT, O'Connell RL, Joly F, *et al*. Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line (≥3) chemotherapy - The GCIG Symptom Benefit Study (SBS). *Gynecol Oncol* 2020;156:45–53.

13 King MT, Stockler MR, O'Connell RL, *et al*. Measuring what matters most: validation of the measure of ovarian symptoms and treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. *Qual Life Res* 2018;27:59–74.

14 King MT, Stockler MR, Butow P, *et al*. Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer. *Int J Gynecol Cancer* 2014;24:865–73.

15 Aaronson NK, Ahmedzai S, Bergman B, *et al*. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993;85:365–76.

16 Osoba D, Zee B, Pater J, *et al*. Psychometric properties and responsiveness of the EORTC quality of life questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. *Qual Life Res* 1994;3:353–64.

17 Greimel E, Bottomley A, Cull A, *et al*. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. *Eur J Cancer* 2003;39:1402–8.

18 Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, *et al*. Reliability and validity of the functional assessment of cancer therapy-ovarian. *J Clin Oncol* 2001;19:1809–17.

19 Jensen SE, Rosenbloom SK, Beaumont JL, *et al*. A new index of priority symptoms in advanced ovarian cancer. *Gynecol Oncol* 2011;120:214–9.

20 Gundy CM, Fayers PM, Groenvold M, *et al*. Comparing higher order models for the EORTC QLQ-C30. *Qual Life Res* 2012;21:1607–17.

21 Giesinger JM, Kieffer JM, Fayers PM, *et al*. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. *J Clin Epidemiol* 2016;69:79–88.

22 King MT, Costa DSJ, Aaronson NK, *et al*. QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30. *Qual Life Res* 2016;25:625–36.

23 King MT, Viney R, Pickard AS, *et al*. Australian utility weights for the EORTC QLU-C10D, a multi-attribute utility instrument derived from the cancer-specific quality of life questionnaire, EORTC QLQ-C30. *Pharmacoeconomics* 2018;36:225–38.

24 Oskay-Özcelik G, Alavi S, Richter R, *et al*. Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the International NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries. *Ann Oncol* 2018;29:910–6.

25 Santini D, Armento G, Giusti R, *et al*. Management of orphan symptoms: ESMO clinical practice guidelines for diagnosis and treatment†. *ESMO Open* 2020;5.

26 Loprinzi CL, Lacchetti C, Bleeker J, *et al*. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. *J Clin Oncol* 2020;38:3325–48.

27 Hay CM, Courtney-Brooks M, Lefkowits C, *et al*. Symptom management in women with recurrent ovarian cancer: do patients and clinicians agree on what symptoms are most important? *Gynecol Oncol* 2016;143:367–70.

28 Chandwani KD, Zhao F, Morrow GR, *et al*. Lack of patient-clinician concordance in cancer patients: its relation with patient variables. *J Pain Symptom Manage* 2017;53:988–98.

29 Kotronoulas G, Kearney N, Maguire R, *et al*. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. *J Clin Oncol* 2014;32:1480–501.

30 Cleeland CS, Wang XS, Shi Q, *et al*. Automated symptom alerts reduce postoperative symptom severity after cancer surgery: a randomized controlled clinical trial. *J Clin Oncol* 2011;29:994–1000.

31 Basch E, Deal AM, Kris MG, *et al*. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. *J Clin Oncol* 2016;34:557–65.

32 Ishaque S, Karnon J, Chen G, *et al*. A systematic review of randomised controlled trials evaluating the use of patient-reported outcome measures (PROMs). *Qual Life Res* 2019;28:567–92.

33 Basch E, Deal AM, Dueck AC, *et al*. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. *JAMA* 2017;318:197–8.

34 Kurtz J-E, Gebski V, Sukhin V, *et al*. Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: a position paper from the GCIG Symptom Benefit Committee. *Gynecol Oncol* 2021;161:502–7.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Int J Gynecol Cancer

The University of Sydney

NHMRC Clinical Trials Centre

GYNECOLOGIC CANCER INTERGROUP

An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers

ANZ GCIG

PoCoG

Psycho-oncology Co-operative Research Group

ANZGOG-0701

Does Palliative Chemotherapy Improve Symptoms in Women with Recurrent Ovarian Cancer?

Measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum resistant or refractory ovarian cancer

Version 3.0

1st February, 2011

Study Chairs

Professor Michael Friedlander	**Professor Phyllis Butow**
Prince of Wales Hospital	**Brennan MacCallum Building**
RANDWICK NSW 2031	**The University of Sydney NSW 2006**

Investigators

Madeleine King	PoCoG, University of Sydney
Corona Gainford	NHMRC Clinical Trials Centre, University of Sydney
Martin Stockler	NHMRC Clinical Trials Centre, University of Sydney
Merryn Voysey	NHMRC Clinical Trials Centre, University of Sydney
Amit Oza	Princess Margaret Hospital, Toronto, Canada
Brigitte Miller	Gynaecologic Cancer Intergroup
Heidi S Donovan	University of Pittsburgh, School of Nursing

Coordinating Centre: NHMRC Clinical Trials Centre
Level 2, 6-10 Mallett Street
Camperdown NSW 2050 Australia
Telephone: 61-2-9562-5000
Fax: 61-2-9562-5094

TABLE OF CONTENTS

CONFIDENTIAL

PROTOCOL AUTHORISATION PAGE

PROTOCOL Code: ANZGOG-0701

Version: 2.0 Dated: 29 March 2010

Does Palliative Chemotherapy Improve Symptoms in Women with Recurrent Ovarian Cancer?

—_____

Professor Michael Friedlander (protocol author)   ***Date***

—_____

Professor Phyllis Butow (protocol author)   ***Date***

—_____

Professor Val Gebski (statistician)   ***Date***

Note: Original and signed document held at the NHMRC Clinical Trials Centre

---

ABBREVIATIONS

ANZGOG	Australian and New Zealand Gynaecological Oncology Group
CA125	Cancer Antigen
CRF	Case Report Form
CTC	Clinical Trial Centre
ECOG	Eastern Cooperative Oncology Group
EORTC	European Organisation for Research and Treatment of Cancer
FACT-O	Functional Assessment of Cancer Therapy - Ovarian
FOSI	FACT Ovarian Symptom Index
GCIG	Gynaecologic Cancer InterGroup
GCP	Good Clinical Practice
HADS	Hospital and Anxiety Depression Scale
HREC	Human Research Ethics Committee
HRQL	Health Related Quality of Life
ICF	Informed Consent Form
MOST	Measure of Ovarian Cancer Symptoms and Treatment Concerns
NCI CTC	National Cancer Institute Common Toxicity Criteria
NHMRC	National Health and Medical Research Council
DRSW	Disease Related Symptoms and Well-being
ATRC	Additional Treatment Related Concerns
PI	Principal Investigator
PIS	Patient Information Sheet
PoCoG	Psycho-Oncology Cooperative Research Group
PS	Performance Score
Pt DATA Form	Patient Disease and Treatment Assessment Form
QL/QoL	Quality of Life
QLQ-C30	EORTC Core QOL Questionnaire C30
QLQ-Ov28	EORCT Ovarian QOL Questionnaire Ov28
RECIST	Response Evaluation Criteria in Solid Tumours
SRQ	Symptom Representation Questionnaire
TMC	Trial Management Committee

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Int J Gynecol Cancer

PROTOCOL SYNOPSIS

Sponsor	University of Sydney
Study Design	Prospective observational cohort study conducted in 2 stages.
Aims	The purpose of this study is to develop a measure of symptom benefit that can be used as an endpoint in clinical trials of palliative chemotherapy.
	The aim of stage 1 is to determine the aspects of HRQL that are most troublesome pre-treatment, the changes in scores with treatment for each of these aspects, measures of hope, anxiety and depression and to identify optimal questionnaire(s) for assessing these aspects and changes in them.
	The aims of stage 2 are to develop criteria for defining symptom benefit, to determine how many women obtain this benefit, and to investigate prognostic models for benefit, time to progression and survival.
Primary Objectives	Stage 1: To determine the aspects of HRQL that are rated most severe and most noticed by patients, and the aspects that are most common
	Stage 2: To determine criteria for defining a clinically significant subjective improvement and the optimal instrument/s to measure benefit
Target Population	Stage 1: Women with recurrent platinum resistant or refractory ovarian cancer that are commencing 2nd or subsequent line chemotherapy as well as patients who are receiving > 3 lines of chemotherapy for recurrent ovarian cancer.
	Stage 2: Women from collaborating GCIG centers who have platinum resistant/refractory epithelial ovarian, fallopian tube or primary peritoneal cancers who are about to start 2nd or subsequent line chemotherapy.

Questionnaires

Stage 1	SRQ
	FACT-O
	EORTC QLQ C30 + Ov-28
	Patient Data Form
	Expected and perceived benefit
	HADS
	Herth Hope Index
Stage 2	MOST (recent and change)
	FACT-0
	EORTC QLQ C30 + Ov-28
	Expected and perceived benefit

Sample size Stage 1: 50 - 100 pts. Stage 2: 800 pts (about 100 per country)

1

1.0 BACKGROUND INFORMATION

Ovarian cancer is the leading cause of death in women with gynecological malignancies in the Western World and an important cause of cancer related deaths in women. The majority of women present with advanced disease and following debulking surgery receive platinum based chemotherapy, typically carboplatin and paclitaxel for 6 cycles. Most patients with advanced ovarian cancer initially respond to treatment but the majority, will relapse. The median time to progression is about 12-18 months and median overall survival of women with advanced ovarian cancer is 2-4 years (1). The median survival after recurrence is 2 years ,but this is variable and depends on multiple factors including initial response to treatment and time to progression.

The majority of women who relapse will be offered further chemotherapy with the likelihood of benefit related, in part to the initial response and the duration of response (2-6).The goals of treatment include controlling/palliating disease-related symptoms, maintaining or improving quality of life, delaying time to progression, and possibly prolonging survival. Many active agents (platinum, paclitaxel, topotecan, liposomal doxorubicin, docetaxel, gemcitabine, and etoposide) are available and more recently some patients are being treated with targeted therapies such as angiogenesis inhibitors.The choice of treatment is based on many factors including the individual clinician's perceived likelihood of benefit of chemotherapy for the patient, potential toxicity of treatment and patient convenience.Only a minority of patients are treated on clinical trials.

Women who relapse greater than 6 months after primary chemotherapy are classified as potentially "platinum sensitive" and usually receive further platinum based combination chemotherapy with response rates ranging from 27-65% and have a median survival of 12-18 months (2-6). Patients who relapse and progress within 6 months of completing first line chemotherapy are classified as "platinum resistant" and have a median survival of 6- 9 months and a 10-30% likelihood of responding to further chemotherapy (2-6). Patients who do not respond or progress while on treatment are classified as having "platinum refractory" disease. As a general rule objective response rates to chemotherapy in patients with platinum refractory ovarian cancer are low and less than 20% (2). "

Patients with platinum refractory and resistant ovarian cancer are commonly treated with chemotherapy and may have a number of lines of therapy depending on prior response, performance status, patient request and/doctor recommendations . Although response rates are low, there is a general perception that more patients have a subjective benefit, but this is poorly studied. It is increasingly appreciated that it is essential to measure and better quantitate the palliative benefit of therapy given that there are many potential side effects of treatment and the objective response rates are low and duration of response relatively short. The results of a recent study comparing topotecan with liposomal doxorubicin in women with recurrent ovarian cancer are a sobering reminder of the low response rates and poor prognosis particularly among women with platinum resistant ovarian cancer and underscore the importance of measuring symptom benefit in patients on chemotherapy. In a subset analysis of platinum-resistant patients, the median time to progression ranged from of 9.1 and 13.6 weeks for topotecan and liposomal doxorubicin respectively. The median survival (P=0.46) was 35.6 weeks for pegylated liposomal doxorubicin and 41.3 weeks for topotecan. Objective response rates of 6.5% for topotecan and 12.3% for pegylated liposomal doxorubicin were not significantly different (P=0.12) (7) which clearly demonstrates the limitations of chemotherapy in this patient population.

There is a paucity of information on the symptom benefits, either perceived or real, of "palliative chemotherapy" in women with platinum resistant or refractory recurrent ovarian cancer. Unfortunately, no large, randomized, controlled trials have yet demonstrated   that systemic chemotherapy improves symptom palliation and quality of life in patients with relapsed ovarian cancer and this is the main reason for treatment.. It is not clear what proportion of women are symptomatic when they commence treatment and whether their symptoms improve as a result of treatment. The published literature on symptoms of women with recurrent ovarian cancer includes not only symptoms that can be attributed to recurrent disease ,but also those associated with prior chemotherapy such as neurotoxicity and fatigue as well as those associated with prior surgery such as menopausal symptoms and fertility issues in younger women. While these are all important and can impact on quality of life, they can not really be used to assess the benefit of palliative chemotherapy. It is essential and clinically important to determine whether symptoms that

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Int J Gynecol Cancer

can be attributed to disease are improved with palliative chemotherapy and whether symptom benefit correlates with more objective measures of treatment effect such as CA125 response or RECIST response

There are only a relatively small number of studies that have addressed questions regarding patient perceptions and expectations of treatment for recurrent ovarian cancer. Doyle et al reported on a prospective study that included 27 patients with recurrent ovarian cancer prior to commencing either 2nd or 3rd line chemotherapy in Toronto (7). All were counseled about the aims and objectives of therapy and all agreed to participate in the study. Well validated questionnaires were used to assess palliative benefit and a questionnaire to evaluate patient expectations was also administered. Objective response to treatment was documented in 20% of patients and the median survival was 11 months. 65% of women expected that chemotherapy would make them live longer and 42% thought it would cure them despite the fact that they had been given verbal and written information that the treatment was palliative. Quality of life, particularly emotional function, was reported to be improved in 60% of patients raising questions as to whether it the treatment per se or the fact that the patient is having treatment that is important.

Donovan et al reported on a study of treatment preferences in recurrent ovarian cancer using a decision board in 81 patients receiving first line chemotherapy and 75 non cancer controls (8). The majority of women with ovarian cancer said they would have further chemotherapy if they relapsed but said they would switch from palliative chemotherapy to palliative care alone when the median survival was reduced to 5 months. How applicable this information is questionable as the women were all receiving first line therapy and none had recurrent ovarian cancer.

Penson et al reported a joint study from the USA and UK and addressed attitudes to chemotherapy in patients with ovarian cancer (9).122 patients were enrolled and 61% had recurrent ovarian cancer (9). Patients thought that second line chemotherapy was associated with remission in 50% of people treated and cure in 15%, which is reminiscent of the Toronto study. Patients were generally optimistic and would accept treatment for relatively little benefit and this is a common finding in studies of treatment for other cancers.

The common thread in these three studies was that treatment provides hope and this is an important need in patients with recurrent ovarian cancer. Although palliative chemotherapy is administered to improve symptom control and delay time to progression the provision of hope is possibly as important to individual patients. This is evident in a number of studies and is in keeping with clinical experience. Quality of life may possibly be of secondary importance to many women with recurrent ovarian cancer who are faced with a life threatening illness. It is clear that asking women who don't have cancer what they would do in a hypothetical situation provides information that is quite different to that obtained from women with recurrent ovarian cancer and this is not surprising. Donovan et al remarked that patients seemed to derive hope from clinical uncertainty and the fact that treatment might help while they perceived that palliative care meant no hope or death (8). All this needs to be considered when assessing the impact or benefit of palliative chemotherapy. Hope, anxiety and depression will be measured in stage 1 using relevant scales.

Response rates are a relatively crude way of defining benefit and clinical trials of palliative chemotherapy should also include subjective measures of benefit. The small study by Doyle suggested that quality of life and emotional well being improved in 50-60% of women receiving 2nd line therapy while only 7 of 27 had objective evidence of benefit (7). These observations should be confirmed, and clinical benefit measures that incorporate both objective response and subjective improvement should be used when evaluating the effect of palliative chemotherapy in women with recurrent ovarian cancer. Symptom relief without survival benefit is achievable in pancreatic cancer and lung cancers and it is important to determine if this is also the case in women with ovarian cancer.

The experience from gastrointestinal cancer and lung cancer in particular clearly demonstrates the utility of using symptom improvement as a primary endpoint of palliative chemotherapy and targeted therapies. The majority of patients with lung cancer die of disease and many experience debilitating symptoms such as pain, dyspnoea and fatigue. The three most common QOL instruments are the EORTC QLQ-C30 which includes the the lung cancer module LC13, the Lung Cancer Symptom Scale (LCSS) which includes a questionnaire based on lung cancer symptoms

reported by the patient and observer and the FACT-L. There is good evidence to show that chemotherapy provides improvement in cancer related symptoms and QOL over supportive care alone. Interestingly, the proportion of patients who have symptom relief is higher than objective response rates suggesting that patients who did not attain the threshold for objective response achieved clinical benefit. (10) There is also good evidence to show similar palliative benefits for targeted therapies such as erlotinib compared to placebo. Patients receiving erlotinib had a significantly longer time to deterioration of cough, dyspnoea and pain as well improvement in these symptoms in about 40% of patients which is accompanied by significant improvements in physical function.(11) These studies serve as a good example of how useful it can be to measure symptom benefit and it's likely that this approach can be extrapolated to patients with recurrent ovarian cancer.

This prospective study will also provide a valuable insight into the management of all women with platinum resistant /refractory ovarian cancer from many centers around the world and provide relevant information about the outcomes of patients treated in routine clinical practice rather than a selected group of women participating in clinical trials where the outcomes may be better due to selection bias. We will gain a better understanding of the reasons why treatment is given, what proportion of women have symptoms related to disease, what their expectations of benefit are and what price they pay in terms of toxicity. However, the major objective is to develop a more robust measure of benefit from chemotherapy that incorporates both subjective and objective response and we will then take this forward for use in prospective clinical trials in women with recurrent ovarian cancer.

We have a unique opportunity in this study to address issues that directly concern women with recurrent ovarian cancer and believe that a qualitative study in a selected subgroup of women in Australia may further help to refine the stage 2 study.

We recognize that we are asking patients to fill in a number of questionnaires and that there is some overlap between them. We will inform all women about the objective of the study and the need to develop better ways to measure benefit of treatment. Based on our previous experience we do not expect that patients will object to filling out all these questionnaires provided they are aware of why they are being asked to do so and how we will then modify the questionnaires for stage 2 based on their feedback and the findings of stage 1.

Compliance with questionnaire completion was excellent with no major omissions or problems identified. There was little to differentiate the candidate instruments in terms of distributions of scores, therefore the choice of instruments for inclusion in Stage 2 was largely determined by coverage of the relevant symptoms. It was decided to retain the QLQ-C30, QLQ-Ov28 and FACT-O and the Patient DATA form was modified to become the MOST form. (see appendix 1 for full details)

Prognostic Score

It is well recognised and accepted that patients with platinum resistant/refractory ovarian cancer constitute a heterogeneous group with a variable response to treatment and a variable survival. Patients with recurrent ovarian cancer are characterised according to their treatment free interval or time to recurrence after 1st line platinum based chemotherapy and designated as having platinum sensitive, platinum resistant or platinum refractory disease based on treatment free interval and response to platinum based chemotherapy (12,13,14). However, it is pertinent to consider the findings of a multivariate analysis of predictors of response in 700 platinum pre-treated patients with recurrent ovarian cancer (15). The investigators found that only 3 factors were independent predictors of response and these included serous histology, number of disease sites and tumour size. Time from last treatment was not an independent prognostic factor, but was highly correlated with tumour size which raises questions of how we should define platinum sensitive and platinum resistance. It should be noted that the latter study included all patients with recurrent disease, not just those with "platinum resistant disease" based on currently used definitions. At present, most studies do not stratify patients with platinum resistant /refractory ovarian cancer into prognostic subsets and there is still inconsistency in the definitions of platinum resistant /refractory ovarian cancer. There are no accepted or widely used prognostic indices that

can be used to subcategorise these patients although clinically we recognise that there is significant variability among this group of patients (16, 17).

Traditional Factors	Potential Additional Factors
Performance status	HRQOL
	ECOG status
Response to prior therapy	Symptoms (large volume ascites, abdominal cramping)
Refractory vs. resistant	weight loss
CA125 only vs. measurable disease	
Volume of tumour	Measures of inflammation (CRP, Haemoglobin, WCC, platelets, LDH, alkaline phosphatase)
Number of metastatic sites	CA125 velocity
Histology Serous vs. Clear Cell vs. Mucinous	
Grade	

The traditional factors that predict response to treatment and prognosis in patient with recurrent ovarian cancer are outlined in the table above. There are however a number of other factors that could be potentially incorporated into a prognostic score including patient and tumour related factors. These include patient related factors such HRQOL at entry and we propose that we look at measures of HRQOLat study entry as well as ECOG performance status as it is likely that patients with a good performance status (16) and better HRQOL will have a better outcome. The presence of symptoms and the nature of the symptoms at the time of treatment may be important and we will document whether they have large volume ascites or symptoms of intermittent cramping abdominal pain that could herald a bowel obstruction. There are a number of other potentially important patient related factors and these include weight loss prior to treatment which may correlate with inflammation and the anorexia –cachexia syndrome (18). In addition, the number of sites of disease as well as the volume of tumour may also correlate with response to treatment and survival and all this is readily available and known at study entry but not typically used to predict response or prognosis. It is also clear that tumour related factors are important predictors of response and survival and these include histological subtype and grade (15, 19, 20). In addition, there is growing evidence in a number of tumour types including ovarian cancer to show that markers of inflammation and inflammatory response are of prognostic significance. These include CRP (C Reactive Protein), haemoglobin, white cell and platelet count as well as LDH alkaline phosphatase (18, 21, 22, 23, 24). Finally, it appears that the CA125 velocity may also be of prognostic significance and reflect the biological behaviour and is worthy of further study (25).The aim of designing this prognostic index/risk score is to develop a tool that better predicts patient outcome and this can then be validated in a different set of patients with platinum resistant/recurrent ovarian cancer.

2.0 AIMS

The purpose of this study is to develop a measure of symptom benefit that can be used as an endpoint in clinical trials of palliative chemotherapy.

The aim of stage 1 is to determine the aspects of HRQL that are most troublesome pre-treatment, the changes in scores with treatment for each of these aspects, measures of hope, anxiety and depression and to identify optimal questionnaire(s) for assessing these aspects and changes in them.

The aims of stage 2 are to develop criteria for defining symptom benefit, to determine how many women obtain this benefit, and to investigate prognostic models for benefit, time to progression and survival.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Int J Gynecol Cancer

3.0 OBJECTIVES

Stage 1

Primary Objective

To determine:
1. The aspects of HRQL that are rated most severe and most noticed by patients, and the aspects that are most common

Secondary Objectives
1. The changes in scores for these aspects that occur with treatment
2. The optimal items and questionnaires to measure changes in these aspects
3. Whether these aspects improve with chemotherapy
4. To classify these aspects according to their likelihood of being symptoms due to ovarian cancer or side-effects of its treatment
5. The associations between symptoms, side-effects and aspects of HRQL and anxiety, depression and hope at baseline and longitudinally

Stage 2

Primary Objective

To determine:
1. The criteria for defining a clinically significant subjective improvement and the optimal instrument/s for measuring this benefit

Secondary Objectives
2. The proportion of women benefiting from palliative chemotherapy as defined by the criteria developed above
3. The time to symptom deterioration
4. The proportion of women who receive treatment because they are (a) symptomatic, (b) have rising tumor markers alone, or (c) have imaging evidence of disease progression
5. The percentage of patients who complete 4 or more cycles of treatment
6. The duration of symptom benefit for those who improved
7. The most common, most severe and most noticed symptoms as perceived by patients.
8. To classify these according to their likelihood of being tumor related symptoms or side effects of prior or current therapy
9. How these symptoms change during the treatment period
10. The relationship between objective tumour response, CA 125 response and subjective responses (HRQOL, symptom scores, anxiety, depression)
11. To investigate and develop prognostic models for benefit, time to progression and survival.

4.0 STUDY DESIGN

This is a prospective, observational cohort study conducted in two stages. For the purposes of this study, the term "ovarian cancer" will include epithelial ovarian cancer, primary peritoneal and fallopian tube cancer.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

Int J Gynecol Cancer

5.0 SUBJECT POPULATION

Stage 1
Women with recurrent platinum resistant or refractory ovarian cancer that are commencing 2nd or subsequent line chemotherapy as well as patients who are receiving > 3 lines of chemotherapy for recurrent ovarian cancer.

Stage 2
Women from collaborating GCIG centers who have platinum resistant/refractory ovarian cancers, according to the definition below, who are about to start 2nd or subsequent line chemotherapy.

A specific definition of platinum resistant/refractory disease has been established for this study:

1. **Primary Platinum Resistant**
   Response to 1st line platinum based therapy with recurrence or disease progression within 6 months of completion of treatment
2. **Primary Platinum Refractory**
   Either a lack of response or disease progression during first line platinum based therapy
3. **Secondary Platinum Resistant**
   Response to 2nd line or more lines of platinum based therapy and disease progression within 6 months of treatment
4. **Secondary Platinum Refractory**
   Initial response to 1st line platinum based therapy but either a lack of response or disease progression whilst receiving 2nd or subsequent line of platinum based therapy

5.1 Inclusion criteria

- Age ≥ 18 years
- Clinical diagnosis of epithelial ovarian, peritoneal or fallopian tube cancers
- Recurrent or progressive disease (CA125, radiological or clinical)
- ECOG PS 0-3
- Life expectancy > 3 months
- Planning to start chemotherapy within 2 weeks of registration
- Able to complete questionnaires independently.

6.0 STUDY METHODS

6.1 Registration

Patients will commence treatment within 2 weeks of registration. Patients can be registered by faxing an enrolment form to the NHMRC Clinical Trials Centre at + 61 (0) 2 95625026

6.2 Treatment

This is not a treatment study. The type, duration and frequency of chemotherapy, biological therapy (targeted therapies) will be at the discretion of the treating physician. All supportive therapies and concomitant medications will be given as per usual local practice.

6.3 Duration of the study

Stage 1
Data will be collected at baseline, prior to every treatment cycle for 4 treatment cycles (12 – 16 weeks) and one month post completion of treatment or until disease progression, *whichever comes first*

Stage 2

Data will be collected at baseline, prior to every treatment cycle, 3-4 weeks following completion of chemotherapy, and then 3-4 weekly until disease progression; *whichever comes last.*

6.4 Study Schema

Target population
• ≥ 18 years • ECOG 0 – 3 • Life expectancy of > 3 months   Clinical diagnosis of epithelial ovarian, peritoneal or fallopian tube cancers • Recurrent or progressive disease (CA125, radiological or clinical) • Planning to commence chemotherapy within 2 weeks of registration • Able to complete questionnaires independently

→ Registration →

Data collection
Data will be collected at the following time-points: • Enrolment • Each visit (3 – 4 wkly) • Every three weeks if discontinue chemotherapy without disease progression • Every three months following disease progression until notification of death 10 participants from Australia will be contacted by a professional HRQOL interviewer and invited to participate in a telephone interview regarding their questionnaire responses (the site investigator will be contacted in the first instance)

7.0 OUTCOME ASSESSMENTS

7.1 Patient Reported Outcomes

Patients in stages 1 and 2 will fill out the following questionnaires at the intervals outlined below. It is estimated that it will take 20 - 30 minutes to complete these questionnaires. The measures selected cover the domains of perceived severity of symptoms, quality of life and hope. The measures are psychometrically sound and have been previously found to be sensitive to change and acceptable to ovarian cancer populations.

Stage 1

QoL Instrument	Baseline (within 2 weeks before first cycle)	Before every subsequent cycle of treatment q3 – 4 weekly	4 weeks after starting 4th cycle of treatment or after end of treatment
SRQ	X	X	X
FACT-O	X	X	X
QLQ-C30 + Ov-28	X	X	X
Pt DATA Form	X	X	X
Expected & perceived benefit	X	X	X
HADS	X		X
Herth Hope Index	X		X

Stage 2

QoL Instrument	Baseline (within 2 weeks before first cycle)	Before every subsequent cycle of treatment or until disease progression – whichever comes last* q 3 – 4 weekly	Before cycle 3 (3-4 weeks after day 1 of cycle 2)
MOST (recent status)	X	X	X
MOST (change)			**X**
FACT-O	X	X	X
EORTC QLQ C30 + Ov-28	X	X	X
Expected Benefit Scale	X	X	X
Perceived Benefit Scale		X	X

*includes those patients who cease study treatment but do not progress and continue with follow-up

MOST (change)

This data will only be collected at Cycle 3 and used to determine the minimal clinically important difference which is the primary aim of the study.

Questionnaires to be completed at each time point:

Baseline:
1. MOST – Recent
2. EORTC QLQC30/OV28
3. FACT-O
4. Expected Benefit Scale

Each Cycle or until progression
1. MOST – Recent
2. EORTC QLQC30/OV28
3. FACT-O
4. Expected & Perceived Benefit Scale

Additional Questions for Cycle 3 only – in addition to 'Each Cycle or until progression' booklet
1. MOST – Change

3 – 4 weeks post last cycle of study treatment
1. MOST – Recent
2. EORTC QLQC30/OV28
3. FACT-O
4. Expected & Perceived Benefit Scale

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Int J Gynecol Cancer

Stage 1

Symptom Representation Questionnaire (SRQ) *(26)*
A wide variety of cancer symptom assessment instruments exist but there are limitations to the existing instruments particularly with respect to the study we have in mind. A group in Pittsburgh have recently developed and validated an instrument called the Symptom Representation Questionnaire (SRQ) (12). The SRQ is designed to provide a multi-dimensional assessment of multiple cancer-related symptoms. It was derived from information processing theory and assesses critical cognitive and emotional factors that are known to influence coping and outcomes. It has been validated in women with ovarian cancer. The SRQ is designed to assess the severity of 26 cancer-related symptoms followed by an assessment of five additional important dimensions of a person's three most bothersome symptoms. It appears to be a psychometrically sound and versatile instrument for assessing cognitive and emotional representations of a wide variety of cancer-related symptoms.

Functional Assessment of Cancer Therapy – Ovary (FACT-O) *(27)*
The (Functional Assessment of Cancer Therapy) FACT-G is a self reported measure that assesses four dimensions of well-being: physical, functional, social/family and emotional well-being. An ovarian cancer-specific subscale of the FACT has been developed and can be combined with the FACT-G subscales. Together, these scales are referred to as the FACT-O which consists of 38 items. It has been previously validated and found appropriate as a brief QoL assessment in clinical trials and descriptive studies.

EORTC QLQ-C30 + QLQ-Ov28 *(28)*
The QOL Core Questionnaire 30 (QLQ-C30) was designed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Group in 1991. It initially comprised of 36 items, but has undergone multiple revisions with improvements in the scales which has resulted in the present 30 item measure (EORTC QLQ-C30 version 3), now the most widely used measure in oncology. The ovarian cancer module addresses additional important symptoms and concerns not included in QLQ-C30, and like all EORTC modules, is designed to be used in conjunction with the QLQ-C30.

Patient DATA Form *(29)*
This is a validated 47 item instrument rating a range of symptoms, concerns and functions important to people with advanced cancer. The troublesomeness of each symptom is rated on a uniform scale from 0 = "none at all" to 10 = "worst I can imagine"

Expected and Perceived Benefit
At baseline and before starting chemotherapy patients will answer 'How much do you expect your symptoms to improve with chemotherapy?' using a numeric rating scale from 0 = "none at all" to 10 = "completely". At each of their follow up visits, after starting chemotherapy and **prior** to objective assessment of response, patients will answer: "How much have your symptoms improved with chemotherapy?" using the same scale. Finally, if patients indicate an improvement in symptom control, they will be asked to complete one item on a 5 point Likert scale (ranging from not at all to very much so) asking whether their symptom improvement was enough to affect their overall quality of life.

HADS *(30)*
The Hospital and Anxiety Depression Scale is comprised of 14 items in 2 subscales independently measuring anxiety and depression.

Herth Hope Index *(31)*
The Herth Hope Index measures the degree to which a patient feels they feel help and a sense of meaning in their lives. The scale has three subscales: temporality and future, positive readiness and expectancy, and interconnectedness.

Stage 2

The rationale for the measures included in Stage 2 is presented in Appendix 1, which provides a brief report of Stage 1 analyses. In summary, there was little to differentiate the candidate instruments in terms of distributions of baseline or change scores, so the choice of instruments for inclusion in Stage 2 was largely determined by coverage of the symptoms and aspects of QOL as those most noticed by Stage 1 patients.

MOST – Measure of Ovarian Cancer Symptoms and Treatment Concerns
The MOST is an ovarian cancer symptom benefit instrument, devised specifically for this study. It comprises 35 individual items which provide comprehensive coverage of all the symptoms and aspects of QOL identified as those most noticed by Stage 1 patients in this study and corroborated in a cohort of 421 women dying of ovarian cancer. (32). Each item is on a discrete scale of 0-10, where major symptomatic distress is represented by 10. It is an adaptation of the Pt-DATA form based on the results of the Stage 1 analysis. The changes include additions (two additional items: abdominal bloating and abdominal pain) and deletions (items which were deemed irrelevant to this clinical context, and clinical opinion of the investigators).

There are two forms:
1. Recent status
2. Change in status

The recent status form asks patients to report their perceived levels of symptoms and concerns 'on average during the last 3-4 weeks'. It is divided into sections. The first section addresses disease related symptoms and concerns (18 items). The first 15 of these items refer to disease symptoms and have an objective interpretation by patients. Items 16 and 17 refer to physical and emotional well-being whilst item 18 is a question referring to overall well-being. The second section addresses additional treatment related concerns (17 items). This is an adaptation of the Pt-DATA form based on the results of the Stage 1 analysis. The changes include additions (two additional items: abdominal bloating and abdominal pain) and deletions (items which were deemed irrelevant to this clinical context, and clinical opinion of the investigators).

The change form includes the same items as the recent status form, but asks patients to report their perceived change in levels of symptoms and concerns since 'before you started this course of chemotherapy 6-8 weeks ago'. The recent status form will be administered prior to each cycle of chemotherapy, while the change form will be administered only prior to the third cycle of chemotherapy. The change form will be used to help determine the minimum clinically important difference in the status form scores, as has been done previously (33, 34)

Functional Assessment of Cancer Therapy – Ovary (FACT-O)
EORTC QLQ-C30 + QLQ-Ov28
The decision to include both QLQ-C30/OV28 and FACT-O was based on the need to be able to conduct a robust validation of the MOST against the two current leading candidates for measuring ovarian-specific HRQOL.

Expected and Perceived Benefit
At baseline and before starting chemotherapy patients will be asked to answer 'How much do you expect your symptoms to improve with chemotherapy?' using a numeric rating scale from 0 = "none at all" to 10 = "completely". After their 2nd cycle, and after their final cycle of chemotherapy, patients will be asked: "How much have your symptoms improved with chemotherapy?" using the same scale. If patients indicate an improvement in symptom control, they will be asked to answer the question "How much better is your overall quality of life as a result of your symptoms improving?" on a 4-point, ordinal scale (No better, a little better, moderately better, much better). Patients will also be asked to answer "On balance, how worthwhile has this course of chemotherapy been for you" on a 4-point, ordinal scale (not at all, somewhat, moderately, extremely).

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Int J Gynecol Cancer

7.2 Qualitative Component

A subset of approximately 20 patients from Australia in stage 1 will undertake a telephone interview to ascertain patient opinion about the candidate questionnaires in Stage 1, and to explore how much improvement in QoL is required by patients to make treatment worthwhile. The first 11 interviews were conducted during 2009, and informed the choice of measures for Stage 2 (see Appendix 4). The findings of this qualitative sub-study will also augment other more quantitative approaches to determining the minimum clinically meaningful difference in Stage 2. Further interviews will be conducted, with a slightly modified interview schedule to provide greater insights for the purpose of Stage 2.

7.3 Tumor response assessment

The method of assessing tumor response will be at the discretion of the treating physician and reflects what happens in routine clinical practice. The same method of assessment should be used throughout the study and response must be assessed at a minimum of 6 – 8 week intervals. Tumor response may be assessed clinically, by GCIG criteria for CA125 response or by RECIST criteria as deemed clinically appropriate for the patient.

8.0 END-POINTS

Stage 1
1. Symptoms identified as most noticed
2. HRQOL scores and change in HRQOL as measured by various QOL questionnaires

Stage 2
Primary Endpoint
1. A clinically significant difference as determined by changes in subjective symptoms, objective responses and QoL scores from baseline to post treatment assessment

Secondary Endpoints
1. The proportion of patients experiencing a clinically significant improvement in symptoms
2. Reason for treatment: (a) symptomatic, (b) rising tumor markers alone, or (c) have imaging evidence of disease progression
3. Symptoms rated most severe by patients
4. HRQL scores at baseline, during and after post treatment
5. Causes of major symptoms: ie, predominantly treatment-related, predominantly disease related, or potentially caused by both treatment and disease)
6. Objective tumor response as measured by RECIST or GCIG criteria for CA 125 response
7. Time to symptom deterioration
8. Duration of symptom improvement
9. Time to disease progression
10. Time to death

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

Int J Gynecol Cancer

9.0 STATISTICAL CONSIDERATIONS

9.1 Sample Size

The sample sizes are 50 - 100 for stage 1 and about 800 for stage 2.

This study is a prospective cohort study thus sample size calculations are based on ensuring estimates of those with clinically significant symptom improvement are within an acceptable margin of error. For this study, the acceptable margin of error has ben arbitrarily set at ± 5% and for a 50% proportion, a sample size of 600 patients with evaluable data after 2 cycles of chemotherapy will produce the 95% confidence interval (46%, 54%), within the acceptable bounds. As the variance of a proportion is largest at 50%, proportions different from 50% will yield 95% confidence intervals narrower than +/- 5%. We expect a total of about 800 patients will need to be recruited to provide 600 patients with evaluable data after 2 cycles of chemotherapy based on the experience of stage 1. Patients will be recruited from several countries and cooperative groups. We aim to recruit approximately 100 patients per country or cooperative group and welcome the participation of countries or groups able recruit 50 patients over 12 months.

The sample size of 600 with complete data for stage 2 will provide over 80% power to detect differences of 10% in the proportions of women benefiting from palliative chemotherapy in dichotomised subgroups (based on a 2:1 ratio of patients in subgroups with improvement rates of 15% vs 25%).

9.2 Statistical analysis

Stage 1

The aim is to determine which are the most common and most noticed symptoms in this population of patients. At each assessment period descriptive statistics will be used to rank the symptoms as in order of severity, 'most noticed' and most common.

Correlation and regression analysis will be used to determine the associations between symptoms, side-effects and aspects of HRQL and anxiety, depression and hope at baseline and longitudinally.

Qualitative analysis: The audio-recorded interviews will be transcribed and coded by two investigators for discrete themes using standard qualitative methods. Differences in coding will be resolved after discussion between coders. A final coding frame will be applied to the data to identify themes and characteristic quotes.

Stage 2

Primary objectives:
Cross-sectional validity of the PRO questionnaires at baseline will be assessed by examining baseline distributions, convergent validity, divergent validity, discriminative validity and predictive validity. A detailed analysis plan including a priori hypotheses will be specified before examining the data.

The individual quality of life and symptom benefit scores will be summarized by standard descriptive statistical measures. The QLQ-C30/OV28 and FACT-O will be scored according to standard scoring algorithms for those instruments. The 35 items of the MOST will be scored as 35 single-item scales. For each symptom and domain covered by the MOST and the QLQ-C30/OV28 and/or FACT-O, comparisons across instruments will provide a robust validation of the MOST against the two current leading candidates for measuring ovarian-specific HRQOL.

The study will develop a global measure of clinically significant symptom improvement by examining changes in symptom items from baseline at each time point and the duration of such changes in an exploratory fashion. Patient views on minimum benefit required in individual items as well as global QoL measures will be used to determine the number of items and the change in those items which constitutes improved symptom benefit. Patient views will be derived from both the qualitative interviews and the MOST Change forms administered pre-cycle 3. The latter

methodology has been used previously to determine the minimum clinically important difference in similar contexts (30, 31). The general approach for assessing improvements will be to calculate absolute changes from baseline. Various criterion levels (e.g. 1, 1.5 and 2 points on a 10 point scale) and durations (e.g. 3 and 6 weeks) or improvement will be assessed to determine a criterioun that is both sensitive (avoids false negatives – missing true benefit) and robust (avoids false positives). Relative changes from baseline will also be examined (e.g. 50% reduction from the baseline score). This approach will be applied primarily to individual symptoms, but also to domain subscales (e.g. physical wellbeing, emotional wellbeing) and total scores (e.g. FACT-G overall wellbeing). It is anticipated that benefits will be much more evident in individual symptoms than in domain subscales or total scores.

Since the MOST has been constructed as a comprehensive measure of all the relevant symptoms for this patient population, a *global symptom benefit* measure will also be examined which combines the first 17 items of MOST and constructs a weighted average of these and item 18 (details of this methodology are provided in Lumley et al (Statistics in Medicine 2000)).

Secondary objectives:

To evaluate the proportion of women benefiting from palliative chemotherapy as defined by a clinically significant improvement in HRQL scores, the relationship between changes in perceived symptoms, HRQOL, anxiety and depression and objective tumour response.

Each patient's subjective responses will be categorized as having improved, worsened or remained stable in comparison to baseline according to the criteria defined above.

Best objective tumor response will be categorized as complete or partial response, stable disease, or progressive disease using RECIST and GCIG definitions of response. 3x3 tables of subjective response versus tumour response will be presented.

Subjective response will be further categorised dichotomously as improved or not by combining the stable and worsened groups. To assess the relationship between improvement in subjective responses and improvements in tumour response, 3x2 tables of subjective response versus tumour response will be analysed using a test for trend.

Time to event endpoints will be analysed using the Kaplan-Meier method.

Multivariable prognostic risk models of time-to-event endpoints will be developed using proportional hazards regression, and patients will be classified as low, medium or high risk.

For all other endpoints, summary statistics will be presented (counts and percentages for categorical outcomes and descriptive statistics for continuous outcomes)

A statistical analysis plan with further details of the analyses will be completed and agreed upon prior to the final data analysis.

10.0 SUBJECT FOLLOW-UP

Participation in this study is voluntary; subjects may withdraw at any time. Patients will provide written informed consent to permit access to their health information.

10.1 Maintaining Follow Up and Withdrawal of Patients

In consenting to participate in the study, patients agree to register and attend for all study assessments and data collection. If a patient wishes to withdraw from the study, site staff should explain the importance of maintaining follow-up information on other outcomes. In this case, sites should ask patients permission to have their medical records reviewed for the purposes of following up their progress.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Int J Gynecol Cancer

If the patient explicitly states their wish not to contribute further data to the study (i.e. withdraw their consent to all aspects of the study), the ANZGOG Coordinating Centre should be informed.

11.0 STUDY STRUCTURE

The study is co-ordinated by the NHMRC Clinical Trials Centre, University of Sydney in collaboration with the Australian New Zealand Gynaecological Oncology Group (ANZGOG) and Psycho-Oncology Cooperative Research Group (PoCoG) as well as with collaborating investigators from other GCIG groups. A Trial Management Committee (TMC) will be set up. A Trial Executive Committee may be selected from the TMC in order to expedite decision-making and will be led by the Study Chair.

The TMC will meet regularly during start-up phase, quarterly to 6-monthly thereafter. Face-to-face meetings will occur as permitted by the study budget, preferably at least annually for the TMC.

The TMC responsibilities include protocol development, study planning, monitoring and progress, review of information from related research and implementation of recommendations from other study committees and external bodies (e.g. HRECs).

In addition, the TMC has responsibilities to hospital sites in taking all reasonable steps to ensure the proper conduct of the study as regards ethics, protocol adherence, integrity and validity of the data recorded on the case report forms. Thus, the main duty of the Study Chair is to help the investigators maintain a high level of ethical, scientific, technical and regulatory quality in all aspects of the study.

12.0 ETHICS AND REGULATORY COMPLIANCE

This study will be conducted according to the Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) Therapeutic Goods Administration DSEB July 2000), the interim New Zealand GCR Guidelines and in compliance with applicable laws and regulations within countries. The study will be performed in accordance with the NHMRC Statement on Ethical Conduct in Research Involving Humans (© Commonwealth of Australia 2007) and the principles laid down by the World Medical Assembly in the Declaration of Helsinki 2004. The investigator shall comply with the protocol, except when a protocol deviation is required to eliminate immediate hazard to a subject. In this circumstance the CTC, principal investigator and HREC must be advised immediately.

12.1 Institutional Human Research Ethics Committees (HRECs)

The protocol, patient information sheet (PIS) and informed consent form (ICF) must be approved by a Human Research Ethics Committee in compliance with Good Clinical Practice (GCP) and applicable regulatory requirements.

A copy of the written approval/advice must be sent to the ANZGOG Coordinating Centre, which should outline the documents approved (protocol, patient information sheet and informed consent form) and the date of approval. A copy of the approved patient information sheet and informed consent should also be sent to the ANZGOG Coordinating Centre.

If there are any version changes to the patient information sheet or informed consent forms, these must be submitted to the ANZGOG Coordinating Centre for review PRIOR to use.

12.2 Confidentiality

The study will be conducted in accordance with applicable Privacy Acts and Regulations. All data generated in this study will remain confidential. All information will be stored securely at the NHMRC Clinical Trials Centre, University of Sydney and will only be available to staff directly involved with the study.

Personal data identifying trial subjects will be held securely at the sites according to local institutional requirements for the purpose of follow up after the conclusion of the protocol-specified period. Sites may be asked to submit copies of source documents to CTC e.g. radiology reports,

however, all reports must be de-identified prior to sending, with only patient trial number and initials detailed. The sites will be asked to provide follow up status of the subject (alive or dead).

12.3 Protocol amendments

Changes and amendments to the protocol can only be made by the TMC. Approval of amendments by the Institutional HREC is required prior to their implementation. In some instances, an amendment may require a change to a consent form. The Investigator must receive approval/advice of the revised consent form prior to implementation of the change. In addition, changes to the CRFs, if required, will be incorporated in the amendment.

The investigator should not implement any changes to, or deviations from, the protocol except where necessary to eliminate immediate hazard(s) to trial subject(s).

12.4 Data handling and record keeping

Trial data will be recorded on the CRFs provided. All required data entry fields will be completed. Data corrections will be done according to the instructions provided. The investigator will be asked to confirm the accuracy of completed CRFs by signing key CRFs as indicated.

Source documents pertaining to the trial must be maintained by investigational sites. Source documents may include a subject's medical records, hospital charts, clinic charts, the investigator's subject study files, as well as the results of diagnostic tests such as X-rays, laboratory tests, and electrocardiograms. The investigator's copy of the case report forms serves as part of the investigator's record of a subject's study-related data.

The following information should be entered into the subject's medical record:
a.   Subject's name, contact information and protocol identification.
b.   The date that the subject entered the study, and subject number.
c.   A statement that informed consent was obtained (including the date).
d.   Relevant medical history
e.   Dates of all subject visits and results of key trial parameters.
f.   The date the subject exited the study, and a notation as to whether the subject completed the study or reason for discontinuation.

The data management of all case report forms will be managed centrally at the Clinical Trials Centre. Submission rates and timing of assessment as stipulated in the protocol will be monitored by the CTC. On a regular basis hospital sites will receive feedback on their submission rates and other specific problems pertaining to that hospital site.

All study-related documentation will be maintained for 15 years following completion of the study.

12.5 Study Monitoring

Data from this study will be monitored by Clinical Trials Program staff from the NHMRC Clinical Trials Centre (CTC). Monitoring will include centralized review of CRFs and other study documents for protocol compliance, data accuracy and completeness. Monitoring may include monitoring visits to investigational sites during for source data verification, review of the investigator's site file and drug handling records. The CTC will be given direct access to source documents, CRFs and other study-related documents. By signing the informed consent form, the subject gives authorized CTC staff direct access to their medical records and the study data.

13.0 PUBLICATION POLICY

The TMC will appoint a Writing Committee to draft manuscripts based on the trial data.
Manuscripts will be submitted to peer-reviewed journal(s). The Writing Committee will develop a publication plan, including authorship, target journals and expected dates of publication. This plan will be consistent with ANZGOG and GCIG guidelines.

14.0 REFERENCES

1. Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I. Ovarian Cancer. *Crit Rev Oncol Hemat.* 2006 **60**:159-179

2. Herzog, TJ and Pothuri B. Ovarian cancer: a focus on management of recurrent disease. *Nat Clin Pract Oncol.* 2006 **3**:604-611

3. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow up according to CA125: A North Thames ovary group study. *Ann Oncol.* 1996 **7**:361–364

4. Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. *Br J Cancer* 1989 **59**:650–653

5. Markman M, Rothman R, Hakes T *et al.* Second-line platinum chemotherapy in patients with ovarian cancer previously treated with cisplatin. *J Clin Oncol.* 1991 **9**:389–393

6. 6 Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. *J Clin Oncol.* 2001 **19**:3312-3322

7. Doyle C, Crump M, Pintilie, Oza AM. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. *J Clin Oncol.* 2001 **19**:1266-74

8. Donovan KA, Greene PG, Shuster JL, Partridge EE and Tucker DC. Treatment preferences in recurrent ovarian cancer. *Gynecol Oncol.* 2002 **86**:200-11

9. Penson R, Dignan F, Seiden M, Lee H, Gallagher C, Matulonis U, Olson K, Gibbens I, Gore M. Attitudes to chemotherapy in patients with ovarian cancer. *Gynecol Oncol.* 2004 **94**:427-35

10. Gralla RJ. Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. Oncologist. 2004; 9 (6); 14-24

11. Bezjak A, Tu D, Seymour L, Clark G et al National Cancer Institute of Canada Clinical Trials Group Study BR.21. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2006; **20** ;(24):3831-7

12. G. Blackledge, F. Lawton, C. Redman and K. Kelly, Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials, *Br J Cancer* **59** (1989), pp. 650–653

13. M.E. Gore, I. Fryatt, E. Wiltshaw and T. Dawson, Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds, *Gynecol Oncol* **36** (1990), pp. 207–211.

14. Markman, B. Reichman, T. Hakes, W. Jones, J.L. Lewis Jr and S. Rubin *et al.,* Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin, *J Clin Oncol* **9** (1991), pp. 1801–1805

15. Eisenhauer EA, Vermorken JB, van Glabbeke M: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients. Ann Oncol 8: 963-968, 1997

16. Hoskins P, Tu D, James K, Pater J, Koski B.Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-derived model with test and validation groups.Gynecol Oncol. 1998 Aug;70(2):224-30

17. Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF.A prognostic model for ovarian cancer. Br J Cancer. 2001 Sep 28;85(7):944-52

18. Mahmoud FA, Rivera NI.The role of C-reactive protein as a prognostic indicator in advanced cancer.Curr Oncol Rep. 2002 May;4(3):250-5. Review

19. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS.Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 2008 Jun; 109(3):370-6

20. Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Villa A, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Alletti DG, Ballardini M, Lombardi AV, Sorio R, Mangili G, Priolo D, Magni G, Morabito A. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer. 2008 Sep 1;8:252.

21. Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, Zeillinger R, Leipold H, Lass H, Grimm C, Tempfer CB, Reinthaller A. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer Clin Cancer Res. 2008 Feb 1;14(3):710-4

22. Kodama J, Miyagi Y, Seki N, et al. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999;82:107–10

23. Gungor T, Kanat-Pektas M, Sucak A, Mollamahmutoglu L.The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch Gynecol Obstet. 2009 Jan;279(1):53-6.

24. Di Maio M, Pisano C, Tambaro R, Greggi S, Casella G, Laurelli G, Formato R, Iaffaioli RV, Perrone F, Pignata S.The prognostic role of pre-chemotherapy hemoglobin level in patients with ovarian cancer.Front Biosci. 2006 May 1;11:1585-90

25. Berek JS, Taylor PT, Nicodemus CF.CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. J Immunother. 2008 Feb-Mar; 31(2):207-14

26. Donovan HS, Ward S, Serlin RC. Evaluation of the Symptom Representation Questionnaire (SRQ) for assessing cancer related symptoms. *J Pain Symptom Manag*, In press

27. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, Webster K, Cella D, Hu S, Gershenson DM. Reliability and validity of the functional assessment of cancer therapy-ovarian. *J Clin Oncol*. 2001 **19**:1809-17

28. Aaronson N, Ahmedzai S, Bergman B *et al.*, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. *J Nat Cancer Inst.* 1993 **85**:365–376

29. Coates A, Glasziou P, McNeil D. On the receiving end III: measurement of quality of life during cancer therapy. *Ann Oncol.* 1990 **1**:213–217

30. Moorey S, Greer S, Watson M, et al: The factor structure and factor stability of the Hospital Anxiety and Depression Scale in patients with cancer. *Br J Psychiatry.* 1991 **158**:255-259

31. Herth K Abbreviated instrument to measure hope: development and psychometric evaluation. *J Adv Nurs.* 1992 **17**:1251

32. Herrinton LJ, Neslund-Dudas C, Rolnick SJ, Hornbrook MC, Bachman DJ, Darbinian JA, Jackson JM, Coughlin SS. Complications at the End of Life in Ovarian Cancer. *J Pain Symptom Management.* 2007 **34**:237-243

33. Filippo de Marinis, Jose Rodrigues Pereira, Frank Fossella, Michael C. Perry, Martin Reck, Marc Salzberg, Jacek Jassem, Patrick Peterson, Astra M. Liepa, Patti Moore, and Richard J. Gralla. Lung Cancer Symptom Scale Outcomes in Relation to Standard Efficacy

Supplemental material
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)
Int J Gynecol Cancer

Measures An Analysis of the Phase III Study of Pemetrexed Versus Docetaxel in Advanced Non-small Cell Lung Cancer. J Thorac Oncol. 2008;3: 30–36.

34. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health related quality-of-life scores. J Clin Oncol. 1998; 16: 139-144.

15.0 LIST OF APPENDICES

Appendix 1   Patient Assessment Schedule

Appendix 2   QoL Questionnaires

Measure of Ovarian Cancer Symptoms and Treatment (MOST) – Recent
Measure of Ovarian Cancer Symptoms and Treatment (MOST) – Change
EORTC QLQ – C30
EORTC OV28
FACT-O
Expected Benefit Scale
Perceived Benefit Scale

Appendix 3   Brief report on Stage 1 analysis

Aims, methods, results and rationale for choice of patient reported outcome measures (PRO) for
Stage 2

The University of Sydney

NHMRC Clinical Trials Centre

Appendix 1   Patient Assessment Schedule

Tests & Observations	Registration Baseline	Pre-each cycle of treatment until progression	Pre-cycle 3[1]	Every 6-8 weeks until progression/off study	3 – 4 weeks post last cycle of study treatment	3 monthly following progression[2]
Informed Consent	X					
History	X					
Physical Exam	X	X				
Performance Status (ECOG)	X					X
FIGO stage at initial diagnosis	X					
Life expectancy > 3 months	X					
Type of resistance: (see NOTES) 1. Primary Platinum Resistant 2. Primary Platinum Refractory 3. Secondary Platinum Resistant 4.Secondary Platinum Refractory	X					
Height and weight	X					
Estimated weight 3/12 ago	X					
Date cancer 1st diagnosed	X					
Debulking at initial diagnosis? If yes, status[3]	X					
Secondry debulking surgery for recurrence?	X					
No. of lines of previous treatment for OC	X					
Response to most recent line of therapy[4]	X					
Date of completion of last line of therapy	X					
Date chemotherapy planned to commence	X					
Regimen – drug name, dose, frequency	X					
Reasons for proposed treatment[5]	X					
Investigator Questions: Predicted likelihood of objective response, symptom improvement, how many cycles of treatment do you expect to administer, life expectancy in months **(this information must be obtained from the investigator)**	X					
Symptoms						
Cancer related symptoms	X					
Symptomatic ascites	X					
Symptoms of cramping abdominal pain or intermittent/incomplete bowel obstruction?	X					

Tests & Observations	Registration Baseline	Pre-each cycle of treatment	Pre-cycle 3	Every 6-8 weeks until progression/off study	3 – 4 weeks post last cycle of study treatment	3 monthly following progression[2]
Tumour Related						
Pathology[6]	X					
Grade at initial diagnosis[7]	X					
Extent of disease[8]	X					
Sites of disease[9]	X					
Pre-Treatment Blood Tests ****please note**** these may not all be *routine* for your site						
Absolute Neutrophil Count (ANC)	X					
Platelets	X					
Lymphocytes	X					
Haemoglobin	X					
Serum Albumin	X					
Alkaline Phosphotase	X					
C Reactive Protein	X					
LDH (lactate dehydrogenase)	X					
CA-125	X			X[10]		
CA-125 Velocity[11]	X					
Toxicities						
Toxicity Data[12]	X					
Adverse Events[13]		X				
Tumour Response						
Tumour Response Assessment[14]				X		
Response[15]				X		
Method of Assessment[16]				X		
Response[17]				X		
Symptom benefit or deterioration[18]				X		
Follow-up						
Patient status[19]						X
Has the patient progressed?[20]						X
Reason for ceasing treatment[21]						X
Current treatment[22]						X
Death notification[23]	*Please complete at notification of patient death*					
QoL Questionnaires						
Baseline Booklet[24]	X					
Each cycle of treatment booklet[25]		X				
Cycle 3 additional questions booklet[26]			X			
Post last cycle of study treatment booklet[27]					X	

NOTES:

[1] Additional questions at Cycle 3. To be completed by the patient in addition to the "Each cycle of treatment" booklet

[2] **OR:** every three weeks until progression for those who have ceased study treatment but not progressed, and then three monthly after progression

[3] Status = No residual disease, Residual disease <1cm, Residual disease >1cm, Not applicable, Unknown

[4] Response = CR (complete response), PR (partial response), SD (stable disease), PD (progressive disease), NE (not evaluable)

[5] Reasons = Symptom control/palliation, if asymptomatic, to delay the development of symptoms, Rising   CA125, Radiological evidence of progression

[6] Serous, endometrioid, clear cell, mucinous, transitional, undifferentiated, mixed – please specify, other – please specify

[7] Low Grade or Hi Grade (includes 2 and 3)

[8] Elevated CA125 or measurable disease. If measurable disease, please indicate maximum diameter of largest tumour

[9] Intra-peritoneal tumour, Nodal, Liver/spleen, Lung, Other

[10] CA125 at 6 – 8 weekly <u>only if using CA125 as the Method of Assessment</u> – actual value is not required

[11] Include 3 most recent CA-125 levels in the three months prior to commencing chemotherapy with dates

[12] Symptoms/pre-existing toxicities present at study enrolment

[13] Adverse Events from treatment

[14] Complete the Tumour Response Assessment at 6 – 8 weekly intervals ie. after every second cycle of chemotherapy using CA125, clinical or radiological assessment criteria

[15] Has there been a response since the last assessment?

[16] What was the method of assessment? CA125, clinical assessment, radiological assessment (RECIST). The method of assessment is at the physician's discretion

[17] What was the response? CA125, Clinical response, Radiological response (according to RECIST criteria)

[18] Has there been any symptom benefit or symptom deterioration?

[19] Is the patient alive or dead?

[20] If the patient is alive, has she progressed?

[21] Please list the reason for ceasing treatment ie. completed planned no. of cycles, AE, Tumour progression, clinician preference, patient preference, death, other

[22] Is the patient currently receiving treatment? If yes, please select type of treatment and indicate what line this treatment will be

[23] Please complete the Death Form at notification of death

[24] Baseline is equivalent to pre-Cycle 1

[25] From pre-Cycle 2 onwards. Baseline is equivalent to pre-Cycle 1

[26] Additional questions at Cycle 3 only. Please ensure the patient completes the each cycle of treatment booklet in addition to these additional questions

[27] QoL questionnaires to be completed 3 – 4 weeks post last cycle of study treatment. This is the same booklet as each cycle of treatment booklet

The University of Sydney

NHMRC Clinical Trials Centre

Appendix 2   QoL Questionnaires

Appendix 3   Stage 1 analysis

<u>Brief report on Stage 1 Analysis</u>. (prepared by Madeleine King and Martin Stockler. December 2009)

Rationale for choice of patient reported outcome measures (PRO) for Stage 2

<u>Background</u>: Four questionnaires relating to symptoms and health-related quality of life (QOL) were used in Stage 1: Symptom Representation Questionnaire (SRQ, 66 items), Patient Disease & Treatment Assessment (Pt-DATA Form, 48 items) Functional Assessment of Cancer Therapy Ovarian (FACT-O, 39 items including 8 items of which comprise the FACT Ovarian Symptom Index), EORTC's Quality of Life Questionnaire Core plus ovarian module (QLQ-C30 and QLQ-Ov28, 58 items).

The SRQ and the Pt-DATA Form are both designed to measure clinically important symptoms and other aspects of quality of life (QOL), they have similar layouts, both have item response scales that range from 0 to 10, and both are based on single-item scoring rather than multi-item or domain-based scoring. The QLQ-C30/Ov28 and FACT-O are both designed to measure QOL in cancer clinical trials. They have a similar format and layout, similar response scale, and multi-item domains & scoring, although the QLQ-C30 includes some single items.

There is considerable overlap in terms of the type of symptoms and aspects of QOL covered between these candidate questionnaires, and therefore there is arguably some substitutability. The booklet was deliberately long and repetitive to corroborate findings and help determine the best subset of questionnaires and items for Stage 2.

<u>Aim</u>: to determine which PRO questionnaires to retain for Stage 2

<u>Sample</u>: The 31 patients who were recruited and had completed QOL questionnaires at baseline (before cycle 1) and before cycles 2 and/or 3 by July 2009. Qualitative interviews were conducted with 11 of these patients.

<u>Methods</u>: The prevalence at baseline (pre-cycle 1) of each symptom nominated by women as one of the 'three most noticed symptoms in the last week' (as asked by SRQ) was determined. Summary statistics and frequency distributions were calculated for items and domain scores for each symptom at baseline, and changes in item and domain scores from baseline (before cycle 1) to before cycle 2 and before cycle 3. For each symptom and aspect of QOL, similar items were identified across the candidate questionnaires, and the distributions and summary statistics for both baseline and change scores were compared.

<u>Results</u>: The symptoms most commonly reported as among the 'three most noticed symptoms in the last week' at baseline are listed in rank order in Table 1, and the coverage of these by the questionnaires is given in Table 2. There were no major ceiling or floor effects on any items. The distributions for similar items were similar, both in terms of location and spread. Mean change scores were typically close to zero, with large standard deviations reflecting, improvements in some women and deteriorations in others. For similar items and domains, results were comparable across candidate questionnaires. Interviews with 11 patients indicated that they neither preferred nor disliked any particular questionnaires.

Table 1: The symptoms most commonly reported as among the 'three most noticed symptoms in the last week' at baseline (number and proportion of patients, n=31)

Symptom	Number	Proportion
Fatigue	17	0.55
Pain – General	11	0.35
Abdominal bloating	10	0.32
Sleep Disturbance	9	0.29
Nausea and vomiting	8	0.26
Appetite	7	0.23
Shortness of breath	6	0.19
Bowel disturbances (including constipation)	6	0.19
Pain – abdominal	5	0.16
Numbness/tingling/ discomfort	3	0.10
Hot flashes	3	0.10
Urinary problems	3	0.10
Emotional problems (including depression)	3	0.10

Table 2: Coverage of the most prevalent symptoms by candidate questionnaires

Symptom	SRQ	Pt-DATA	FACT-O	FOSI	QLQ-C30	QLQ-OV28
Fatigue	2	2	1	1	3	-
Pain - General	1	1	1	1	2	-
Abdominal bloating	1	-	1	1	-	1
Sleep disturbance	1	1	1	-	1	-
Nausea & vomiting	2	2	2	2	2	-
Appetite	1	2	1	-	1	1
Shortness of breath	1	1	-	-	1	-
Bowel disturbances	1	2	1	-	2	3
Pain - abdominal	-	-	1	1	-	1
Numbness/tingling/ discomfort	1	1	-	-	-	2
Urinary problems	1	1	-	-	-	1
Emotional problems	1	4	1	1	4	1
Global QOL	-	1	1	1	2	-

Outcome of Stage 1: finalizing questionnaires for Stage 2

Since there was little to differentiate the candidate instruments in terms of distributions of scores, the choice of instruments for inclusion in Stage 2 was largely determined by coverage of the relevant symptoms. It was decided to retain the Pt-DATA form, the QLQ-C30, QLQ-Ov28 and FACT-O. The deciding factor in favour of the Pt-DATA form over the SRQ was that the Pt-DATA form was developed by one of the investigators, A/Prof Martin Stockler and colleagues at the NHMRC Clinical Trials Centre, and it was therefore feasible to adapt it to maximise coverage of the relevant symptoms in one questionnaire for use in future studies beyond Stage 2.. To achieve this, it was decided to add an item on abdominal bloating and another on abdominal pain to the Pt-DATA form to ensure complete coverage of all of the symptoms commonly reported as among the 'three most noticed symptoms in the last week', and to include both 'current status' and 'change' versions to capture both of these aspects of symptoms. The decision to retain both QLQ-C30/OV28 and FACT-O was to allow validation of the modified Pt-DATA forms again the two current standards for assessment of QOL in ovarian cancer, to provide a definitive comparison of the measurement properties of these two QOL measures and the FOSI in this patient population.

The final version of the adapted Pt-DATA form to be used in Stage 2 has been named the **Measure of Ovarian Cancer Symptoms and Treatment Concerns (MOST).**

It contains 35 individual items on a discrete scale of 0-10, where major symptomatic distress is represented by 10. It is an adaptation of the Pt-DATA form based on the results of the Stage 1 analysis. The changes include additions (two additional items: abdominal bloating and abdominal pain) and deletions (items which were deemed irrelevant to this clinical context and clinical opinion of the investigators).

It contains two forms:

1) The recent status form asks patients to report their perceived levels of symptoms and concerns 'on average during the last 3-4 weeks'. It is divided into sections. The first section addresses disease related symptoms and concerns (18 items). The first 15 items refer to disease symptoms and have an objective interpretation by patients. Items 16 and 17 refer to physical and emotional well-being whilst item 18 is a question referring to overall well-being. The second section addresses additional treatment related concerns (17 items).

2) The change form contains the same items as the recent status form, but asks patients to report their perceived change in levels of symptoms and concerns since 'before you started this course of chemotherapy 6-8 weeks ago'. The recent status form will be administered prior to each cycle of chemotherapy, while the change form will be administered only prior to the third cycle of chemotherapy. The change form will be used to help determine the minimum clinically important difference in the status form scores, as has been done previously (33, 34)